Pegylated interferon-alpha-2a: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
 
Line 20: Line 20:
{{CMG}}
{{CMG}}
__NOTOC__
__NOTOC__
{{Editor Help}}
 


==Overview==
==Overview==

Latest revision as of 14:52, 20 August 2012

Pegylated interferon-alpha-2a
Clinical data
Pregnancy
category
  • ?
Routes of
administration		?
ATC code
Legal status
Legal status
  • ?
Pharmacokinetic data
Bioavailability?
Metabolism?
Elimination half-life?
Excretion?
Identifiers
CAS Number
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC860H1353N227O255S9
Molar mass19241 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Pegylated interferon alfa-2a (40kD) (commercial name PEGASYS) is an antiviral drug discovered at the pharmaceutical company F.Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system.

This drug is approved around the world for the treatment of chronic hepatitis C (including patients with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B.

Related Chapters

External links


de:Peginterferon α


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Pegylated_interferon-alpha-2a&oldid=687159"